Eli Health

-56%

est. 2Y upside i

HealthcareSeries A

Eli Health is building the real-time interface to the human body, making it possible to improve both daily and lifelong health through instant access to essential biological signals. Its flagship product, the Hormometer™, is the first instant hormone monitoring system—delivering results from a saliva sample to your phone in minutes.

Rank

#1028

Sector

Digital Health

Est. Liquidity

~5Y

Data Quality

Data: Medium

Eli Health presents a moderate upside opportunity for a job seeker, driven by its innovative instant, saliva-based hormone monitoring system and strong intellectual property.

Last updated: March 10, 2026

Bull (30%)+300%

Eli Health successfully expands its Hormometer platform to a broader range of biomarkers and gains significant market share in the rapidly growing at-home diagnostics sector, driven by its proprietary instant saliva-based technology and strong IP. Revenue scales to over $50M by 2028, justifying a $240M+ valuation at a 4-5x revenue multiple, well above the current estimated $60M.

Base (40%)+50%

Eli Health continues to grow steadily, establishing a niche in continuous hormone monitoring. It faces ongoing competition but maintains its differentiation through product innovation and user experience. Revenue reaches ~$20M by 2028, leading to an acquisition or later-stage funding round at a ~$90M valuation, providing a moderate return for common stock holders.

Bear (30%)-80%

Eli Health struggles with high regulatory barriers, slower-than-expected market adoption, or increased competition from well-funded incumbents or new entrants with similar technology. Revenue growth stalls, leading to a down round or acquisition at a valuation of $12M or less, resulting in minimal to no return for common stock holders due to the severe liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Investors hold $20M in liquidation preferences ahead of common stock on an estimated $60M valuation.

Dilution Risk

high

As a Series A company with high capital intensity, Eli Health will likely require additional significant funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

As an early-stage company, there is currently no active secondary market or tender offers for Eli Health's equity.

Questions to Ask at the Interview

Strategic questions based on Eli Health's data — designed to show you've done your homework.

1
“Eli Health has successfully launched cortisol, testosterone, and progesterone tests. What are the next key biomarkers or health conditions the company plans to address, and how will these expand the TAM and competitive advantage?”
2
“Given the high capital intensity and the current revenue of ~$6M, how does Eli Health plan to achieve profitability or significantly reduce burn rate in the next 2-3 years, especially considering the need for further R&D and manufacturing scale?”
3
“With a significant portion of total funding ($20M) representing liquidation preferences, how does Eli Health envision a liquidity event (IPO or acquisition) that would provide meaningful returns for common stock holders, particularly within a 2-year horizon?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.